Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases

• US 20050265999A1
• Filed: 12/21/2004
• Published: 12/01/2005
• Est. Priority Date: 12/23/2003
• Status: Abandoned Application

• Current Assignee: Myogen, Inc. (Gilead Sciences Inc.), Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Myogen, Inc. (Gilead Sciences Inc.), Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Olson, Eric, Melvin, Lawrence, Bush, Erik
• Application Number:
  US11/018,426
• Publication Number:
  US 20050265999A1
• Time in Patent Office: Days
• US Class Current: 424/143.100
• CPC Class Codes: A61K 31/4365 the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/4706 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/10 Antioedematous agents; Diuretics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/02 Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 2800/321 : Arterial hypertension
• CPC Class Codes: G01N 33/6893 : related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/942 : Serotonin, i.e. 5-hydroxy-tryptamine

Abstract

The present invention provides for methods of treating and preventing muscle atrophy, cardiac hypertrophy, heart failure and/or primary pulmonary hypertension linked to a family of serotonin receptors called 5-HT2 receptors. The present invention further demonstrates that modulators of 5-HT2 receptors can inhibit or treat muscle atrophy, heart failure, cardiac hypertrophy, and/or primary pulmonary hypertension.

Claims

1. A method of treating cardiovascular disease or muscle atrophy in a mammal comprising:

(a) identifying a subject having a cardiovascular disease or muscle atrophy; and

(b) administering to said subject a modulator of a 5-HT2 receptor.

2. The method of claim 1, wherein said modulator acts on a 5-HT2a receptor.

3. The method of claim 1, wherein said modulator acts on a 5-HT2b receptor.

4. The method of claim 1, wherein said modulator acts on a 5-HT2c receptor.

5. The method of claim 1, wherein said modulator acts on more than one 5-HT2 receptor.

6. The method of claim 5, wherein said more than one 5-HT2 receptor consists of a 5-HT2a and a 5-HT2b receptor.

7. The method of claim 5, wherein said more than one 5-HT2 receptor consists of a 5-HT2a and a 5-HT2c receptor.

8. The method of claim 5, wherein said more than one 5-HT2 receptor consists of a 5-HT2b and a 5-HT2c receptor.

9. The method of claim 1, wherein cardiovascular disease consists of heart failure, cardiac hypertrophy, or primary pulmonary hypertension.

10. The method of claim 1, wherein said mammal is a human.

11. The method of claim 1, wherein said modulator is selected from the group consisting of an antibody, an RNAi, a ribozyme, a peptide, a small molecule, an antisense molecule, 3-Methyl-2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-b]pyridin-4-ylamine, and 2-Phenyl-quinolin-4-ylamine.

12. The method of claim 11, wherein the antibody is a monoclonal, polyclonal or humanized antibody, an Fab fragment, or a single chain antibody.

13. The method of claim 1, wherein administering comprises intravenous administration of said modulator.

14. The method of claim 1, wherein administering comprises oral, transdermal, sustained release, suppository, or sublingual administration of said modulator.

15. The method of claim 1, further comprising administering to said subject a second therapeutic regimen.

16. The method of claim 15, wherein said second therapeutic regimen is selected from the group consisting of a beta blocker, an iontrope, diuretic, ACE-I, AII antagonist, histone deacetylase inhibitor, a Ca(++)-blocker, and a TRP channel inhibitor.

17. The method of claim 15 wherein said second therapeutic regimen is administered at the same time as said modulator.

18. The method of claim 15, wherein said second therapeutic regimen is administered either before or after said modulator.

19. The method of claim 1, wherein treating comprises improving one or more symptoms of cardiac hypertrophy.

20. The method of claim 19, wherein said one or more symptoms comprises increased exercise capacity, increased blood ejection volume, left ventricular end diastolic pressure, pulmonary capillary wedge pressure, cardiac output, cardiac index, pulmonary artery pressures, left ventricular end systolic and diastolic dimensions, left and right ventricular wall stress, or wall tension, quality of life, disease-related morbidity and mortality.

21. The method of claim 1, wherein treating comprises improving one or more symptoms of heart failure.

22. The method of claim 21, wherein said one or more symptoms comprises progressive remodeling, ventricular dilation, decreased cardiac output, impaired pump performance, arrhythmia, fibrosis, necrosis, energy starvation, and apoptosis.

23. The method of claim 1, wherein treating comprises improving one or more symptoms of primary pulmonary hypertension.

24. The method of claim 23, wherein said one or more symptoms comprises shortness of breath, right ventricular failure, decreased exercise capacity, elevated right ventricular systolic pressure, elevated pulmonary arterial systolic pressure, dyspnea, syncope, edema, cyanosis, and angina.

25. The method of claim 1, wherein treating comprises improving one or more symptoms of muscle atrophy.

26. The method of claim 25, wherein said one or more symptoms comprises muscle weakness, muscle pain, muscle cramps, muscle aches, paralysis, spasms, seizures, or coordination problems.

35. The method of claim 26, wherein the patient at risk may exhibit one or more of long standing uncontrolled hypertension, uncorrected valvular disease, chronic angina and/or recent myocardial infarction.

27. A method of preventing muscle atrophy, cardiac hypertrophy, primary pulmonary hypertension, or heart failure comprising:

(a) identifying a patient at risk for muscle atrophy, cardiac hypertrophy, primary pulmonary hypertension, or heart failure; and

(b) administering to said patient a modulator of a 5-HT2 receptor.

28. The method of claim 27, wherein said 5-HT2 receptor comprises a 5-HT2a, 5-HT2b, or 5-HT2c receptor.

29. The method of claim 27, wherein said 5-HT2 receptor comprises more than one 5-HT2 receptor.

30. The method of claim 29, wherein said more than one 5-HT2 receptor comprises a 5-HT2a and a 5-HT2b receptor.

31. The method of claim 29, wherein said more than one 5-HT2 receptor comprises a 5-HT2a and a 5-HT2c receptor.

32. The method of claim 29, wherein said more than one 5-HT2 receptor comprises a 5-HT2b and a 5-HT2c receptor.

33. The method of claim 27, wherein administering comprises intravenous administration of said 5-HT2 receptor modulator.

34. The method of claim 33, wherein administering comprises oral, transdermal, sustained release, suppository, or sublingual administration.

36. The method of claim 27, wherein said modulator of a 5-HT2 receptor consists of an antibody, an RNAi, a ribozyme, a peptide, a small molecule, an antisense molecule, 3-Methyl-2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-b]pyridin-4-ylamine, and 2-Phenyl-quinolin-4-ylamine.

37. The method of claim 36, wherein the antibody is a monoclonal, polyclonal or humanized antibody, an Fab fragment, or a single chain antibody.

38. A method of identifying an inhibitor of muscle atrophy, heart failure, primary pulmonary hypertension, or hypertrophy in a mammal comprising:

(a) providing a 5-HT2 receptor modulator;

(b) treating a mammalian myocyte with said 5-HT2 receptor inhibitor; and

(c) measuring the expression of one or more muscle atrophy, cardiac hypertrophy, heart failure, or primary pulmonary hypertension parameters,

wherein a change in said one or more muscle atrophy, cardiac hypertrophy, heart failure, or primary pulmonary hypertension parameters, as compared to one or more said parameters in a myocyte not treated with said 5-HT2 receptor modulator, identifies said 5-HT2 receptor modulator as an inhibitor of muscle atrophy, heart failure, cardiac hypertrophy, or primary pulmonary hypertension.

39. The method of claim 38, wherein said myocyte is subjected to a stimulus that triggers a hypertrophic response in said one or more cardiac hypertrophy parameters.

40. The method of claim 39, wherein said stimulus is expression of a transgene.

41. The method of claim 39, wherein said stimulus is treatment with a chemical agent.

42. The method of claim 38, wherein said one more cardiac hypertrophy parameters comprises the expression level of one or more target genes in said myocyte, wherein expression level of said one or more target genes is indicative of cardiac hypertrophy.

43. The method of claim 42, wherein said one or more target genes is selected from the group consisting of ANF, a-MyHC, b-MyHC, a-skeletal actin, SERCA, cytochrome oxidase subunit VIII, mouse T-complex protein, insulin growth factor binding protein, Tau-microtubule-associated protein, ubiquitin carboxyl-terminal hydrolase, Thy-1 cell-surface glycoprotein, or MyHC class I antigen.

44. The method of claim 42, wherein the expression level is measured using a reporter protein coding region operably linked to a target gene promoter.

45. The method of claim 44, wherein said reporter protein is luciferase, b-gal, or green fluorescent protein.

46. The method of claim 38, wherein the expression level is measured using hybridization of a nucleic acid probe to a target mRNA or amplified nucleic acid product.

47. The method of claim 39, wherein said one or more muscle atrophy or cardiac hypertrophy parameters comprises one or more aspects of cellular morphology.

48. The method of claim 46, wherein said one or more aspects of cellular morphology comprises sarcomere assembly, cell size, cellular fusion, or cell contractility.

49. The method of claim 38, wherein said myocyte is comprised in isolated intact tissue.

50. The method of claim 38, wherein said myocyte is a cardiomyocyte.

51. The method of claim 50, wherein said cardiomyocyte is a neonatal rat ventricular myocyte.

52. The method of claim 50, wherein said cardiomyocyte is located in vivo in a functioning intact heart muscle.

53. The method of claim 52, wherein said functioning intact heart muscle is subjected to a stimulus that triggers heart failure or a hypertrophic response or primary pulmonary hypertension in one or more heart failure, cardiac hypertrophy, or primary pulmonary hypertension parameters.

54. The method of claim 53, wherein said stimulus is aortic banding, rapid cardiac pacing, induced myocardial infarction, osmotic minipump, or transgene expression.

55. The method of claim 54, wherein said one or more cardiac hypertrophy parameters comprises right ventricle ejection fraction, left ventricle ejection fraction, ventricular wall thickness, heart weight/body weight ratio, or cardiac weight normalization measurement.

56. The method of claim 38, wherein said one or more muscle atrophy or cardiac hypertrophy parameters comprises total protein synthesis.

57. A method of identifying an inhibitor of muscle atrophy, heart failure, primary pulmonary hypertension, or hypertrophy in a mammal comprising:

(a) providing a cell expressing an 5-HT2 receptor;

(b) contacting said 5-HT2 receptor inhibitor with a candidate inhibitor substance; and

(c) measuring the effect of the candidate inhibitor substance on the activity or expression of said 5-HT2 receptor,

wherein a decrease in 5-HT2 activity, as compared to 5-HT2 activity in the absence of said candidate inhibitor substance, identifies said candidate inhibitor substance as an inhibitor of muscle atrophy, heart failure, cardiac hypertrophy or primary pulmonary hypertension.

58. The method of claim 57, wherein said cell is a myocyte.

59. The method of claim 58, wherein said myocyte is located in vivo in a functioning muscle cell.

60. The method of claim 58, wherein said myocyte is a cardiomyocyte.

61. The method of claim 60, wherein said cardiomyocyte is located in vivo in a functioning intact heart muscle.

62. The method of claim 57, wherein expression is measured using hybridization of a nucleic acid probe to a 5HT-2 mRNA or amplified nucleic acid.

63. The method of claim 57, wherein expression is measured using an antibody to 5HT-2.

64. The method of claim 57, wherein activity is measured by assessing expression of one or more target genes, expression of which is stimulated by 5HT-2 receptor activation.